🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Targeted therapies are reshaping mBC treatment—but where are they taking us? Drs. Callahan & Bardia talk evolution, biomarkers & the power of clinical-research collaboration. 🎧 Full convo on CHM Conversations. #Oncology #mBC #BreastCancer #TargetedTherapies #CHMConversations

Sequencing matters. Drs. Callahan & Bardia break down how timing and strategy shape outcomes in HER2+ mBC—and why one-size-fits-all doesn’t work. 🎧 Full discussion via CHM Conversations. #HER2 #TDXd #Oncology #BreastCancer #CHMConversations

📢 At #ASCO25, first results from DESTINY-Breast09 (#DB09) showed that T-DXd + pertuzumab outperformed standard THP in 1L HER2+ MBC. Dr. @jamouabbi & @PTatantinoMD discuss how this regimen could reshape frontline treatment in #HER2+ metastatic breast cancer

Jason Mouabbi and Paolo Tarantino Discuss How T-DXd + Pertuzumab Could Reshape Frontline Treatment in HER2+ mBC Community Health Media Paolo Tarantino Jason A. Mouabbi MD oncodaily.com/blog/paolo-tar… #Cancer #CancerResearch #Medicine #Health #BreastCancer #mBC #Pertuzumab #MedX #MedNews #MedEd

TDXd for Brain Metastases 🧠 Drs. Rena Callahan from David Geffen School of Medicine at UCLA and Aditya Bardia from UCLA Health illustrate how TDXd has become the preferred treatment for #HER2-breast #cancer patients with brain #metastases, reshaping clinical practice standards. #tdxd #breastcancer

Innovation means nothing if we don’t talk about access. Drs. Callahan & Bardia dig into timing, strategy & making sure new therapies like T-DXd truly reach the right patients. 🎧 Full convo on CHM Conversations. #HER2 #Oncology #TDXd #BreastCancer #CHMConversations

Innovation in HER2+ breast cancer care continues to accelerate—but how do we ensure it’s applied with precision? In this episode of CHM Conversations, Drs. Jason A. Mouabbi MD and MichelinaCairo explore how clinical nuance, evolving data, and the patient experience all intersect to

HER2+ care is evolving fast. Drs. Jason A. Mouabbi MD & MichelinaCairo break down how new therapies are shifting the day-to-day decisions doctors make—and why adaptability matters. #TDXd #HER2 #Oncology #BreastCancer #CHMConversations #CommunityHealthMedia

Science is only part of the story. Drs. Jason A. Mouabbi MD & MichelinaCairo talk about what it takes to align evolving HER2+ options with what truly matters to each patient. 🎧 Watch now on CHM Conversations. #BreastCancer #HER2 #OncologyCare #CHMConversations #CommunityHealthMedia

In HER2+ breast cancer, the when matters as much as the what. Drs. Jason A. Mouabbi MD & MichelinaCairo talk about timing, treatment shifts & why clinical instinct still counts. 🎧 Watch now via CHM Conversations. #HER2 #OncologyCare #BreastCancer #CHMConversations

The HER2+ treatment playbook is changing—and so are second-line decisions. Drs. Jason A. Mouabbi MD & MichelinaCairo talk strategy, timing & what oncologists need to watch next. 🎥 Full clip on CHM Conversations. #HER2 #TDXd #OncologyUpdates #BreastCancerCare #CHMConversations

HER2 isn’t just positive or negative anymore. Drs. Jason A. Mouabbi MD & MichelinaCairo dig into what shifting HER2 definitions mean for diagnosis and treatment planning. 🎧 CHM Conversations has the full clip. #HER2Low #Oncology #BreastCancer #Pathology #CHMConversations

Clinical data matters—but so does the person in front of you. Drs. Jason A. Mouabbi MD & MichelinaCairo share how oncologists navigate evolving HER2+ options while keeping patient needs front and center. 🎥 Watch now on CHM Conversations. #HER2 #OncologyCare #BreastCancer

Uncertainty in treatment? It happens. What matters is how we talk about it. Drs. Jason A. Mouabbi MD & MichelinaCairo discuss the value of honest, clear communication in HER2+ breast cancer care. 🎧 Full clip on CHM Conversations. #HER2 #Oncology #SharedDecisions #CHMConversations

HER2 testing is evolving—and so are the conversations around it. Drs. Jason A. Mouabbi MD & MichelinaCairo explain why accuracy, context, and collaboration are key. 🎥 Full clip on CHM Conversations. #HER2 #Oncology #BreastCancerCare #CHMConversations #CommunityHealthMedia